RAPP - Latest News
Rapport Therapeutics, Inc. Common Stock (RAPP), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.27B. Beta to the broader market is 0.97.
The article list below shows the most recent RAPP headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent RAPP Headlines
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
globenewswire.com - Aug 5, 2026
RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania o
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86
defenseworld.net - Jul 18, 2026
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven ratings firms
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
fool.com - Jul 12, 2026
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41. 58 per share.
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com - Jun 8, 2026
Rapport Therapeutics, Inc.
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com - May 20, 2026
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biote
How News Affects RAPP Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RAPP's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked RAPP news questions
- What is the latest RAPP news headline?
- The most recent RAPP headline (Aug 5, 2026) is "Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the RAPP news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What RAPP news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual RAPP options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.